Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Total Assets
Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) holds total assets worth CN¥6.82 Billion CNY (≈ $997.38 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 688076 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Total Assets Trend (2013–2025)
This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See 688076 net asset value for net asset value and shareholders' equity analysis.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total assets of CN¥6.82 Billion consist of 37.3% current assets and 62.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.6% |
| Accounts Receivable | CN¥500.68 Million | 7.4% |
| Inventory | CN¥859.52 Million | 12.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥453.57 Million | 6.7% |
| Goodwill | CN¥156.34 Million | 2.3% |
Asset Composition Trend (2013–2025)
This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688076 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinopep-Allsino Biopharmaceutical Co. Ltd. A's current assets represent 37.3% of total assets in 2025, an increase from 7.6% in 2013.
- Cash Position: Cash and equivalents constituted 13.6% of total assets in 2025, up from 5.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 13.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 12.8% of total assets.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 1.06 | 5.35 |
| Quick Ratio | 0.75 | 0.73 | 4.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥360.63 Million | CN¥116.44 Million | CN¥846.51 Million |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Sinopep-Allsino Biopharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.26 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 32.7% |
| Total Assets | CN¥6.74 Billion |
| Market Capitalization | $1.27 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sinopep-Allsino Biopharmaceutical Co. Ltd. A's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sinopep-Allsino Biopharmaceutical Co. Ltd. A's assets grew by 32.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
The table below shows the annual total assets of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.74 Billion ≈ $986.32 Million |
+32.74% |
| 2024-12-31 | CN¥5.08 Billion ≈ $743.07 Million |
+43.15% |
| 2023-12-31 | CN¥3.55 Billion ≈ $519.07 Million |
+40.64% |
| 2022-12-31 | CN¥2.52 Billion ≈ $369.09 Million |
+18.59% |
| 2021-12-31 | CN¥2.13 Billion ≈ $311.23 Million |
+52.40% |
| 2020-12-31 | CN¥1.40 Billion ≈ $204.22 Million |
+12.14% |
| 2019-12-31 | CN¥1.24 Billion ≈ $182.11 Million |
+18.43% |
| 2018-12-31 | CN¥1.05 Billion ≈ $153.77 Million |
+71.86% |
| 2017-12-31 | CN¥611.47 Million ≈ $89.48 Million |
+281.90% |
| 2016-12-31 | CN¥160.11 Million ≈ $23.43 Million |
-18.59% |
| 2015-12-31 | CN¥196.67 Million ≈ $28.78 Million |
+29.75% |
| 2014-12-31 | CN¥151.58 Million ≈ $22.18 Million |
-9.13% |
| 2013-12-31 | CN¥166.81 Million ≈ $24.41 Million |
-- |
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more